白内停品牌怎么样 申请店铺

我要投票 白内停在滴眼液行业中的票数:224 更新时间:2025-04-04
白内停是哪个国家的品牌?「白内停」是远大医药(中国)有限公司旗下著名品牌。该品牌发源于湖北省武汉市,在1939年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力白内停品牌出海!通过在本页面挂载白内停品牌的产品链接和联系邮箱,可以提高白内停产品曝光!跨境电商爆单神器,目前只要100元/年哦~

白内停怎么样

其眼科用药尤为有名,集各类制剂、医疗器械和化学原料药等系列产品的研发、生产、销售于一体的综合性医药企业。

远大医药(远大医药(中国)有限公司,英文名称为Grand Pharmaceutical (China) Co., Ltd.)是一家拥有70多年辉煌历史的现代医药集团,前身为八路军太行山革命根据地的一个制药所,曾为抗日战争和解放战争做出巨大贡献。2002年加入中国远大集团,2008年成为母公司香港上市公司——远大医药健康控股有限公司(股票代码:HK0512)的核心企业。

远大医药目前拥有十多家成员企业,是集各类制剂、医疗器械和化学原料药于一体的综合性医药企业。公司的核心产品涵盖五官科、心血管急救制剂/器械、生物技术和特色原料药为代表的三大业务领域,形成以欣维宁为核心的心血管用药;以瑞珠和白内停为核心的眼科用药;以切诺、诺通为核心的耳鼻喉科用药;以眼表检测试纸和眼科手术耗材为核心的医疗器械;以及利用多种生物工程技术制备的氨基酸及其衍生物产品群。近年来,远大医药通过推进战略转型,转变发展方式,加快自主创新,不断拓展产品市场,经营发展整体态势良好,销售收入和利润每年保持30%以上的增长。

远大医药始终秉持“敢为人先,共享成功”的企业精神,以“提供好产品,修炼高境界”为经营理念,围绕转型升级,不断提升企业的核心业务优势,创造新的需求通过现代化管理平台和专业化技术平台,推动着企业向现代化和国际化目标迈进,努力成为受中国医生和患者尊重的制药企业。

Its ophthalmic medicine is particularly famous. It is a comprehensive pharmaceutical enterprise integrating R & D, production and sales of various preparations, medical devices and chemical raw materials. Yuanda Pharmaceutical (China) Co., Ltd., English name is grand Pharmaceutical (China) Co., Ltd.), a modern pharmaceutical group with a glorious history of more than 70 years, formerly a Pharmaceutical Institute in Taihang Mountain revolutionary base of the Eighth Route Army, has made great contributions to the Anti Japanese War and the war of liberation. In 2002, he joined China Yuanda Group, and in 2008, he became the core enterprise of Hong Kong listed parent company Yuanda pharmaceutical health Holding Co., Ltd. (Stock Code: hk0512). With more than ten member enterprises, Yuanda pharmaceutical is a comprehensive pharmaceutical enterprise integrating various preparations, medical devices and chemical APIs. The company's core products cover the three business areas represented by the Department of facial features, cardiovascular first-aid agents / devices, biotechnology and characteristic APIs, forming cardiovascular drugs with Xinweining as the core; ophthalmic drugs with Ruizhu and bainetone as the core; otolaryngology drugs with chenuo and notong as the core; medical devices with eye surface test paper and ophthalmic surgical consumables as the core; And amino acids and their derivatives produced by various bioengineering technologies. In recent years, through the promotion of strategic transformation, transformation of development mode, acceleration of independent innovation, continuous expansion of product market, good overall situation of business development, sales revenue and profit growth of more than 30% every year. Yuanda pharmaceutical always adheres to the enterprise spirit of "dare to be the first, share success", takes "provide good products, cultivate high realm" as the business philosophy, around the transformation and upgrading, continuously improves the core business advantages of the enterprise, creates new needs, through the modern management platform and professional technology platform, promotes the enterprise to move forward towards the goal of modernization and internationalization, and strives to become a recipient of Chinese medicine Pharmaceutical companies with respect to health and patients.

本文链接: https://brand.waitui.com/d0aa3d4ad.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

美国2月贸易逆差1227亿美元

美国商务部普查局4月3日发布数据,2月贸易逆差1227亿美元,预估为逆差1235亿美元,前值为逆差1314亿美元。(界面)

2小时前

美股大型科技股盘前普跌,苹果跌超7%

36氪获悉,美股大型科技股盘前普跌,截至发稿,苹果、亚马逊跌超7%,特斯拉、Arm、英伟达跌超6%,Meta跌超5%,谷歌跌超4%,微软、奈飞跌超3%。

2小时前

热门中概股美股盘前普跌,拼多多跌超6%

36氪获悉,热门中概股美股盘前普跌,截至发稿,拼多多跌超6%,京东跌超5%,百度、爱奇艺、阿里巴巴、B站、蔚来跌超3%,理想汽车跌超2%,网易、腾讯音乐、微博跌超1%。

2小时前

高测股份:控股股东张顼拟询价转让4.99%股份

36氪获悉,高测股份公告,公司控股股东张顼计划通过询价转让方式转让27,308,000股,占公司总股本的4.99%,转让原因为自身资金需求。出让方声明所持股份权属清晰,不存在限制或禁止转让情形,且不违反相关减持规定和承诺。本次询价转让的受让方需为具备相应定价能力和风险承受能力的机构投资者。本次询价转让的价格下限不低于发送认购邀请书之日(即2025年4月3日)前20个交易日高测股份股票交易均价的70%。

2小时前

欧盟成员国拟表决对美关税反制措施

欧盟高级官员4月3日表示,欧盟成员国计划9日投票表决针对美方25%钢铝关税的反制措施。欧盟委员会负责贸易和经济安全等事务的委员马罗什·谢夫乔维奇表示,不合理的关税最终只会适得其反,欧盟将以冷静、有步骤且团结一致的方式作出回应。(新华社)

2小时前

本页详细列出关于贝复舒的品牌信息,含品牌所属公司介绍,贝复舒所处行业的品牌地位及优势。
咨询